Compare iShares Core MSCI EAFE ETF (IEFA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Mesoblast Limited — how do they compare? iShares Core MSCI EAFE ETF trades at $100.9, while Mesoblast Limited trades at $16.87 (market cap $2.21B). The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| IEFA | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $101.09 | $20.96 |
52-Week Low | $84.72 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $101.28, up 0.75% today, with a bullish technical outlook from moving averages but overbought RSI signals. The ETF focuses on developed international markets excluding the U.S. and Canada, offering diversification and a dividend yield. Recent news highlights its role in defensive portfolio shifts and comparisons with peers like VXUS and SPGM.
Outlook is positive for diversification seekers amid U.S. concentration risks, supported by lower fees and income appeal. Risks include developed-market economic sensitivity and currency fluctuations. Analyst sentiment is generally favorable for long-term exposure.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
